WHY
RSS will be consider to suspend till emergency end in Aug by SC
Most probably next week announcement
Good Luck shorties

JN88 JPMorgang Director confirmed will buy back all Topglove shares that have been short for the pass one month.... this is insider news.... The effort of their analysts Jefferey NG to give the TP as low as 3.5 is achieved. their target is not 3.5 , but your tickets that selling at Rm 5.5 -6.5......

WHY
RSS will be consider to suspend till emergency end in Aug by SC
Most probably next week announcement
Good Luck shorties

JN88 JPMorgang Director confirmed will buy back all Topglove shares that have been short for the pass one month.... this is insider news.... The effort of their analysts Jefferey NG to give the TP as low as 3.5 is achieved. their target is not 3.5 , but your tickets that selling at Rm 5.5 -6.5......

WHY
RSS will be consider to suspend till emergency end in Aug by SC
Most probably next week announcement
Good Luck shorties

JN88 JPMorgang Director confirmed will buy back all Topglove shares that have been short for the pass one month.... this is insider news.... The effort of their analysts Jefferey NG to give the TP as low as 3.5 is achieved. their target is not 3.5 , but your tickets that selling at Rm 5.5 -6.5......

Tesla's Price Target Raised by J.P Morgan After Deliveries Data
A long-time bear on Tesla raises his share-price target on the electric car company after it reported strong third-quarter deliveries.
DAN WEIL OCT 5, 2020 10:00 AM EDT

Tesla (TSLA) - Get Report rose Monday after J.P. Morgan analyst Ryan Brinkman, a long-time bear, raised his share-price target on the electric car company after it reported strong third-quarter deliveries last week.

Brinkman’s not exactly a raging bull. He lifted the share-price target to only $75 from $65. That compares to a recent quote of $423.17, up 1.95% from Friday and up an astronomical 406% year to date through Friday.

Brinkman also maintained his underweight rating.

Bitcoin (BTC USD) Price, News, Quotes: JPMorgan Sees ...www.bloomberg.com › news › articles › jpmorgan-sees...
Jan 5, 2021 — JPMorgan Says Bitcoin Could Surge to $146,000 in Long Term Bitcoin has the potential to reach $146,000 in the long term as it competes with gold as an asset class, according to JPMorgan Chase & Co.

Bitcoin (BTC USD) Price, News, Quotes: JPMorgan Sees ...www.bloomberg.com › news › articles › jpmorgan-sees...
Jan 5, 2021 — JPMorgan Says Bitcoin Could Surge to $146,000 in Long Term Bitcoin has the potential to reach $146,000 in the long term as it competes with gold as an asset class, according to JPMorgan Chase & Co.

Tesla's Price Target Raised by J.P Morgan After Deliveries Data
A long-time bear on Tesla raises his share-price target on the electric car company after it reported strong third-quarter deliveries.
DAN WEIL OCT 5, 2020 10:00 AM EDT

Tesla (TSLA) - Get Report rose Monday after J.P. Morgan analyst Ryan Brinkman, a long-time bear, raised his share-price target on the electric car company after it reported strong third-quarter deliveries last week.

Brinkman’s not exactly a raging bull. He lifted the share-price target to only $75 from $65. That compares to a recent quote of $423.17, up 1.95% from Friday and up an astronomical 406% year to date through Friday.

Brinkman also maintained his underweight rating.

JPM TP for Tesla USD 75.00

Tesla Inc
NASDAQ: TSLA
826.16 USD −18.84 (2.23%)
Closed: 15 Jan, 7:59 pm GMT-5 · Disclaimer
After hours 823.77 −2.39 (0.29%)

JPM TP Bitcoin USD 146,000.00

1 Bitcoin equals
34,480.10 United States Dollar
17 Jan, 10:19 am UTC · Disclaimer

gloveisover Spread so much fake news still can’t reach TP 3.50 Aiyo LCLY


gloveisover Spread so much fake news still can’t reach TP 10. Aiyo, sad nia. At least JPM and co were right lo since the price went down a lot.

JPM TP for Tesla USD 75.00

Tesla Inc
NASDAQ: TSLA
826.16 USD −18.84 (2.23%)
Closed: 15 Jan, 7:59 pm GMT-5 · Disclaimer
After hours 823.77 −2.39 (0.29%)

JPM TP Bitcoin USD 146,000.00

1 Bitcoin equals
34,480.10 United States Dollar
17 Jan, 10:19 am UTC · Disclaimer

gemfinder gloveisover LCLY

RSS will be consider to suspend til emergency end in Aug
Most probably next week announcement
Good Luck shorties

RSS will be consider to suspend til emergency end in Aug
Most probably next week announcement
Good Luck shorties

Tesla's Price Target Raised by J.P Morgan After Deliveries Data
A long-time bear on Tesla raises his share-price target on the electric car company after it reported strong third-quarter deliveries.
DAN WEILOCT 5, 2020 10:00 AM EDT

Tesla (TSLA) - Get Report rose Monday after J.P. Morgan analyst Ryan Brinkman, a long-time bear, raised his share-price target on the electric car company after it reported strong third-quarter deliveries last week.

Brinkman’s not exactly a raging bull. He lifted the share-price target to only $75 from $65. That compares to a recent quote of $423.17, up 1.95% from Friday and up an astronomical 406% year to date through Friday.

Brinkman also maintained his underweight rating.

But as for the positives, “we are raising our estimates to account for 3Q deliveries which exceeded our expectations and that of consensus, but which appear to have fallen short of likely elevated investor expectations,” the analyst said,

Tesla said last Thursday that deliveries for the three months ended in September hit a record 139,300.

“We are introducing 2022 estimates, looking for EPS of $3.35 vs. $2.50 in 2021 and $1.85 in 2020,” Brinkman said. He boosted his share-price target “on account of our new, higher out-year estimates.”

Tesla's Price Target Raised by J.P Morgan After Deliveries Data
A long-time bear on Tesla raises his share-price target on the electric car company after it reported strong third-quarter deliveries.
DAN WEILOCT 5, 2020 10:00 AM EDT

Tesla (TSLA) - Get Report rose Monday after J.P. Morgan analyst Ryan Brinkman, a long-time bear, raised his share-price target on the electric car company after it reported strong third-quarter deliveries last week.

Brinkman’s not exactly a raging bull. He lifted the share-price target to only $75 from $65. That compares to a recent quote of $423.17, up 1.95% from Friday and up an astronomical 406% year to date through Friday.

Brinkman also maintained his underweight rating.

But as for the positives, “we are raising our estimates to account for 3Q deliveries which exceeded our expectations and that of consensus, but which appear to have fallen short of likely elevated investor expectations,” the analyst said,

Tesla said last Thursday that deliveries for the three months ended in September hit a record 139,300.

“We are introducing 2022 estimates, looking for EPS of $3.35 vs. $2.50 in 2021 and $1.85 in 2020,” Brinkman said. He boosted his share-price target “on account of our new, higher out-year estimates.”

J.P. Morgan Sees Doom and Gloom in Tesla Stock Despite ...finance.yahoo.com › j-p-morgan-sees-doom-011224214
Dec 9, 2020 — On December 21, Tesla's (TSLA) long wait to be included in the S&P 500 comes to an end. Having proven itself capable of turning a profit for ...
Missing: tp ‎| Must include: tp

J.P. Morgan Sees Doom and Gloom in Tesla Stock Despite ...finance.yahoo.com › j-p-morgan-sees-doom-011224214
Dec 9, 2020 — On December 21, Tesla's (TSLA) long wait to be included in the S&P 500 comes to an end. Having proven itself capable of turning a profit for ...
Missing: tp ‎| Must include: tp

Tesla (TSLA) Shares Are 'Dramatically Overvalued' JPMorgan ...www.bloomberg.com › news › articles › tesla-shares-ar...
Dec 9, 2020 — Tesla Inc.'s shares are now “dramatically” overvalued and investors thinking of raising their holdings in the company ahead of its impending

Tesla (TSLA) Shares Are 'Dramatically Overvalued' JPMorgan ...www.bloomberg.com › news › articles › tesla-shares-ar...
Dec 9, 2020 — Tesla Inc.'s shares are now “dramatically” overvalued and investors thinking of raising their holdings in the company ahead of its impending

Bitcoin (BTC USD) Price, News, Quotes: JPMorgan Sees ...www.bloomberg.com › news › articles › jpmorgan-sees...
Jan 5, 2021 — JPMorgan Says Bitcoin Could Surge to $146,000 in Long Term Bitcoin has the potential to reach $146,000 in the long term as it competes with gold as an asset class, according to JPMorgan Chase & Co.

Bitcoin (BTC USD) Price, News, Quotes: JPMorgan Sees ...www.bloomberg.com › news › articles › jpmorgan-sees...
Jan 5, 2021 — JPMorgan Says Bitcoin Could Surge to $146,000 in Long Term Bitcoin has the potential to reach $146,000 in the long term as it competes with gold as an asset class, according to JPMorgan Chase & Co.

BALANCE_VIEW gemfinder .....u r such a moorroon! force labour? Then how about this? Malaysia is a gold mine to them? Only moorroonn will believe the hypocrisy of mat salleh. And just bcos of an old recycle clips, you got excited ! How low can you go ??

https://www.therakyatpost.com/2020/11/04/theres-a-protest-in-banglades...

PZOGRO HOT!

JP MORGAN NAMES "EXTREMELY CHEAP UNDERVALUED" HEALTHCARE STOCKS WHICH ARE NOW TRADING EXTREMELY CHEAP, UNDERPERFORMED THE MARKET AND HAVE POTIVE EARNINGS MOMENTUM"

TOPGLOVE, SUPERMX IN THE LIST?!

https://www.cnbc.com/2021/01/13/value-stocks-jpmorgan-names-extremely-...
17/01/2021 9:28 AM

https://www.bloomberg.com/news/articles/2021-01-16/norway-vaccine-fatalities-among-people-75-and-older-rise-to-29

Norway has registered a total of 29 deaths among people over the age of 75 who’ve had their first Covid-19 vaccination shot, raising questions over which groups to target in national inoculation programs.

The latest figure adds six to the number of known fatalities in Norway, and also lowers the age group thought to be affected from 80.

Norway has registered a total of 29 deaths among people over the age of 75 who’ve had their first Covid-19 vaccination shot, raising questions over which groups to target in national inoculation programs.

The latest figure adds six to the number of known fatalities in Norway, and also lowers the age group thought to be affected from 80.

https://www.bloomberg.com/news/articles/2021-01-16/norway-vaccine-fatalities-among-people-75-and-older-rise-to-29

https://www.globaltimes.cn/page/202101/1212746.shtml



19% or 95%? US expert challenges Pfizer vaccine’s efficacy, triggers debates in China
By Leng Shumei and Bai Yunyi
Published: Jan 13, 2021 10:55 PM
Could the Pfizer vaccine's real efficacy be as low as 19 percent, instead of 95 percent as it claims?

Questions raised by Peter Doshi, an assistant professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, have triggered heated discussion on Chinese social media.

Doshi's opinion was disputed among Chinese vaccine experts interviewed by the Global Times. Many experts agreed that Pfizer should provide more raw data for peer review but said Doshi's methodology may be flawed.

Chinese experts also noted that disputes often arise from clinical trial data of COVID-19 vaccines, given the difference in participant groups and how different pharmaceutical companies define COVID-19 symptoms differently. They said that the efficacy rate of a vaccine should be evaluated in a more comprehensive manner, citing Sinovac as an example.

Sinovac vaccine received a 50.3-percent efficacy rate on Wednesday, based on phase III clinical trials in Brazil. But the figure was largely due to the fact that participants in Brazil are all medical workers with a very high infection risk, experts said.

Doshi on January 4 released an article on a blog platform under the UK pharmaceutical journal The BMJ, questioning Pfizer's efficacy rate.

Pfizer revealed that it discovered 170 PCR confirmed COVID-19 cases during the phase III clinical trials and 3,410 suspected cases in total.

However, if taking these suspected cases all as confirmed ones, the Pfizer vaccine's efficacy would be dramatically reduced to 19 percent. Even after omitting cases occurring within seven days of vaccination, which should include the majority of symptoms due to short-term vaccine reactogenicity, the efficacy rate remains as low as 29 percent, Doshi said in the article.

Doshi also questioned the standards of how Pfizer excluded cases and the influence of the use of medication on the vaccine's efficacy.

Doshi's comments triggered controversy on Chinese social media platforms, with some Chinese experts doubting Doshi's counting method for efficacy as he takes all participants showing symptoms to be confirmed COVID-19 cases, even if PRC tests show negative results.

"The PRC test is of very high sensitivity, 98.6 percent in the last year. But its sensitivity could be only 5 percent under Doshi's counting method," Zhuang Shilihe, a Guangzhou-based vaccine doctor, told the Global Times on Wednesday.

Zhuang noted that Doshi's doubts may be related to the anti-vaccine movement in the US, noting that Doshi has previously criticized other vaccines like the flu vaccines.

A Beijing-based vaccine expert who required anonymity expressed distrust of Pfizer's efficacy, but he did not directly comment on Doshi's doubts.

Despite different opinions on the Pfizer vaccine's efficacy, both experts said that Pfizer should reveal the raw data for peer review to better analyze the vaccine, so as to exclude the influence of any environmental or other elements on the efficacy.

https://www.globaltimes.cn/page/202101/1212746.shtml



19% or 95%? US expert challenges Pfizer vaccine’s efficacy, triggers debates in China
By Leng Shumei and Bai Yunyi
Published: Jan 13, 2021 10:55 PM
Could the Pfizer vaccine's real efficacy be as low as 19 percent, instead of 95 percent as it claims?

Questions raised by Peter Doshi, an assistant professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, have triggered heated discussion on Chinese social media.

Doshi's opinion was disputed among Chinese vaccine experts interviewed by the Global Times. Many experts agreed that Pfizer should provide more raw data for peer review but said Doshi's methodology may be flawed.

Chinese experts also noted that disputes often arise from clinical trial data of COVID-19 vaccines, given the difference in participant groups and how different pharmaceutical companies define COVID-19 symptoms differently. They said that the efficacy rate of a vaccine should be evaluated in a more comprehensive manner, citing Sinovac as an example.

Sinovac vaccine received a 50.3-percent efficacy rate on Wednesday, based on phase III clinical trials in Brazil. But the figure was largely due to the fact that participants in Brazil are all medical workers with a very high infection risk, experts said.

Doshi on January 4 released an article on a blog platform under the UK pharmaceutical journal The BMJ, questioning Pfizer's efficacy rate.

Pfizer revealed that it discovered 170 PCR confirmed COVID-19 cases during the phase III clinical trials and 3,410 suspected cases in total.

However, if taking these suspected cases all as confirmed ones, the Pfizer vaccine's efficacy would be dramatically reduced to 19 percent. Even after omitting cases occurring within seven days of vaccination, which should include the majority of symptoms due to short-term vaccine reactogenicity, the efficacy rate remains as low as 29 percent, Doshi said in the article.

Doshi also questioned the standards of how Pfizer excluded cases and the influence of the use of medication on the vaccine's efficacy.

Doshi's comments triggered controversy on Chinese social media platforms, with some Chinese experts doubting Doshi's counting method for efficacy as he takes all participants showing symptoms to be confirmed COVID-19 cases, even if PRC tests show negative results.

"The PRC test is of very high sensitivity, 98.6 percent in the last year. But its sensitivity could be only 5 percent under Doshi's counting method," Zhuang Shilihe, a Guangzhou-based vaccine doctor, told the Global Times on Wednesday.

Zhuang noted that Doshi's doubts may be related to the anti-vaccine movement in the US, noting that Doshi has previously criticized other vaccines like the flu vaccines.

A Beijing-based vaccine expert who required anonymity expressed distrust of Pfizer's efficacy, but he did not directly comment on Doshi's doubts.

Despite different opinions on the Pfizer vaccine's efficacy, both experts said that Pfizer should reveal the raw data for peer review to better analyze the vaccine, so as to exclude the influence of any environmental or other elements on the efficacy.

Germany - vaccine death !!

https://www.republicworld.com/world-news/europe/10-dead-in-germany-wit...

Last Updated: 15th January, 2021 09:18 IST
10 Dead In Germany Within 4 Days Of Covid-19 Vaccine Inoculation; Probe Ordered
German specialists probe as 10 people died soon after getting inoculated against the novel Coronavirus disease, the deceased were aged between 79 to 93 years.
Written By
Astha Singh
facebook

After the deaths of 10 people who passed away soon after having been inoculated against the novel coronavirus disease, Specialists from Germany's Paul Ehrlich Institute are looking into it. Brigitte Keller-Stanislawski, the head of the institute's department of the safety of medicinal products and medical devices, said on Thursday.

READ | COVID-19: Two WHO Team Members To Wuhan Test Positive, Being Retested In Singapore

The deceased were aged between 79 to 93, all with antecedent diseases. The time between vaccination and death ranged from several hours to four days, according to the medical expert.

"Until yesterday we had nine cases; we have to wait for the data from Lower Saxony [about another alleged case], then there will be 10. We are talking about patients in extremely grave condition, with multiple diseases, who were receiving palliative treatment. I have already said that we are studying these cases ... Based on our current data we assume they died from their main diseases, coinciding in time with the vaccination," Keller-Stanislawski said at a press conference.

https://www.globaltimes.cn/page/202101/1212915.shtml

Chinese health experts call to suspend Pfizer's mRNA vaccine for elderly after Norwegian deaths
By Zhang Hui
Published: Jan 15, 2021 01:58 PM


Chinese health experts called on Norway and other countries to suspend the use of mRNA-based COVID-19 vaccines produced by companies such as Pfizer, especially among elderly people, due to the vaccines' safety uncertainties following the deaths of 23 elderly Norwegian people who received the vaccine.

The new mRNA vaccine was developed in haste and had never been used on a large scale for the prevention of infectious disease, and its safety had not been confirmed for large-scale use in humans, a Chinese immunologist said.

The death incidents in Norway also proved that the mRNA COVID-19 vaccines' efficacy was not as good as expected, experts said.

As of Thursday, Norway has reported 23 deaths in connection with vaccination.

"So far, 13 of these have been assessed. Common side effects may have contributed to a severe course in frail elderly people," the Norwegian Medicines Agency said on its website.

Chinese health experts call to suspend Pfizer's mRNA vaccine for elderly after Norwegian deaths
By Zhang Hui
Published: Jan 15, 2021 01:58 PM


Chinese health experts called on Norway and other countries to suspend the use of mRNA-based COVID-19 vaccines produced by companies such as Pfizer, especially among elderly people, due to the vaccines' safety uncertainties following the deaths of 23 elderly Norwegian people who received the vaccine.

The new mRNA vaccine was developed in haste and had never been used on a large scale for the prevention of infectious disease, and its safety had not been confirmed for large-scale use in humans, a Chinese immunologist said.

The death incidents in Norway also proved that the mRNA COVID-19 vaccines' efficacy was not as good as expected, experts said.

As of Thursday, Norway has reported 23 deaths in connection with vaccination.

"So far, 13 of these have been assessed. Common side effects may have contributed to a severe course in frail elderly people," the Norwegian Medicines Agency said on its website.

https://www.globaltimes.cn/page/202101/1212915.shtml

All RSS tapao next week
Suspension of RSS

PZOGRO HOT!

SUSPENSION RSS IDSS WAITING WAHID TO APPROVE!!!


FLY FLY FLY!!

Very good news

Most probably will announce tonight

Norway: 23 Dead after Receiving Pfizer, BioNTech Vaccine
Ahmed Moamar by Ahmed Moamar 11:01 PM January 14, 2021

https://see.news/norway-23-dead-after-receiving-pfizer-biontech-vaccine/

Norway: 23 Dead after Receiving Pfizer, BioNTech Vaccine
Ahmed Moamar by Ahmed Moamar 11:01 PM January 14, 2021

https://see.news/norway-23-dead-after-receiving-pfizer-biontech-vaccine/

https://www.cnbc.com/2021/01/13/moderna-ceo-says-the-world-will-have-to-live-with-the-coronavirus-forever.html?__source=androidappshare&fbclid=IwAR3jSA8K8apgwAL2nZDsPgA1KvXAA_XFMHioJdADREL66JtRMfxtnP_t1Bs

https://www.cnbc.com/2021/01/13/moderna-ceo-says-the-world-will-have-to-live-with-the-coronavirus-forever.html?__source=androidappshare&fbclid=IwAR3jSA8K8apgwAL2nZDsPgA1KvXAA_XFMHioJdADREL66JtRMfxtnP_t1Bs

Moderna CEO says the world will have to live with Covid ‘forever’
PUBLISHED WED, JAN 13 20213:07 PM ESTUPDATED WED, JAN 13 20215:00 PM EST
Berkeley Lovelace Jr.
@BERKELEYJR
SHARE
Share Article via Facebook
Share Article via Twitter
Share Article via LinkedIn
Share Article via Email
KEY POINTS
Stephane Bancel, CEO of Covid-19 vaccine maker Moderna, warned Wednesday that the virus will be around “forever.”
Public health officials and infectious disease experts have said there is a high likelihood that Covid-19 will become an endemic disease, meaning it will be present at all times, though likely at lower levels than it is now.
“SARS-CoV-2 is not going away,” Bancel said during a panel discussion at the JPMorgan Healthcare Conference.

Moderna CEO says the world will have to live with Covid ‘forever’
PUBLISHED WED, JAN 13 20213:07 PM ESTUPDATED WED, JAN 13 20215:00 PM EST
Berkeley Lovelace Jr.
@BERKELEYJR
SHARE
Share Article via Facebook
Share Article via Twitter
Share Article via LinkedIn
Share Article via Email
KEY POINTS
Stephane Bancel, CEO of Covid-19 vaccine maker Moderna, warned Wednesday that the virus will be around “forever.”
Public health officials and infectious disease experts have said there is a high likelihood that Covid-19 will become an endemic disease, meaning it will be present at all times, though likely at lower levels than it is now.
“SARS-CoV-2 is not going away,” Bancel said during a panel discussion at the JPMorgan Healthcare Conference.

Share of China Intco all time high RMB 243.99
52-wk high 257.70
52-wk low 13.98


Intco Medical Technology Co Ltd
SHE: 300677
243.99 CNY +14.03 (6.10%)
13 Jan, 4:29 pm GMT+8 · Disclaimer

Open 227.26
High 257.70
Low 227.26
Mkt cap 81.00B
P/E ratio 18.89
Div yield 0.16%
Prev close 229.96
52-wk high 257.70
52-wk low 13.98

Share of China Intco all time high RMB 243.99
52-wk high 257.70
52-wk low 13.98


Intco Medical Technology Co Ltd
SHE: 300677
243.99 CNY +14.03 (6.10%)
13 Jan, 4:29 pm GMT+8 · Disclaimer

Open 227.26
High 257.70
Low 227.26
Mkt cap 81.00B
P/E ratio 18.89
Div yield 0.16%
Prev close 229.96
52-wk high 257.70
52-wk low 13.98

JPM got no more excuse to create fear for glove stocks even small issue of not using glove to administer vaccine in Singapore also big news to them
What a shameful CB Morgan
Why most country using glove when administer vaccine using glove never mention?
JPM IB who wrote the report must be name HK Chan

JPM got no more excuse to create fear for glove stocks even small issue of not using glove to administer vaccine in Singapore also big news to them
What a shameful CB Morgan
Why most country using glove when administer vaccine using glove never mention?
JPM IB who wrote the report must be name HK Chan

MOH predicts it will take 3 months to flatten the curve at current rate
Hariz Mohd

Published 13 Jan 2021, 7:22 pm
Modified 8:12 pm
30
Health director-general Dr Noor Hisham Abdullah said the Health Ministry (MOH) projects that it would take 12 weeks to flatten the curve of Covid-19 new cases.

This projection was based on current Health Ministry data which Noor Hisham said could change after two weeks of movement control order (MCO).

"What's important is that we stay on the right track and adhere to the guidelines. Stay at home. If you have to go out, wear a mask, wash your hands and keep your distance. Hopefully, that will reduce new cases.

"In terms of flattening the curve, we expect to see it in 12 weeks. We will implement (the MCO) for two weeks. We'll see later if we need (to take further action).

MOH predicts it will take 3 months to flatten the curve at current rate
Hariz Mohd

Published 13 Jan 2021, 7:22 pm
Modified 8:12 pm
30
Health director-general Dr Noor Hisham Abdullah said the Health Ministry (MOH) projects that it would take 12 weeks to flatten the curve of Covid-19 new cases.

This projection was based on current Health Ministry data which Noor Hisham said could change after two weeks of movement control order (MCO).

"What's important is that we stay on the right track and adhere to the guidelines. Stay at home. If you have to go out, wear a mask, wash your hands and keep your distance. Hopefully, that will reduce new cases.

"In terms of flattening the curve, we expect to see it in 12 weeks. We will implement (the MCO) for two weeks. We'll see later if we need (to take further action).

Deal's off if vaccine doesn’t pass muster, KJ assures amid doubts about Sinovac
A Phase III clinical trial in Brazil finds Sinovac vaccine to be only 50.4 percent efficacious.